A New Approach to In Vivo Transformation of Killer T Cells

Area of Science:

• Biotechnology
• Immunotherapy
• Gene Therapy

Background:

• Chimeric antigen receptor (CAR) T cell therapy transforms T cells to target diseased cells.
• Traditional CAR T cell therapy is patient-specific, lengthy, and costly.
• In vivo gene delivery methods are being developed to overcome these limitations.

Purpose of the Study:

• To explore in vitro and in vivo aspects of CAR T cell therapy.
• To evaluate virus-like particles (VLPs) for in vivo CAR gene delivery.
• To compare VLPs with existing gene delivery vectors.

Main Methods:

• Preparation of VLPs from CAR-encoding mRNA and viral capsid protein.
• Functionalization of VLPs with T cell-targeting antibodies.
• Assessment of VLP stability, CAR expression in T cells, and in vitro/in vivo efficacy.

Main Results:

• VLPs demonstrated unique stoichiometric preciseness and thermodynamic stability.
• Monodisperse spherical VLPs were RNase resistant and induced strong CAR expression.
• Proposed in vitro and in vivo experiments to validate efficacy against HIV-infected cells.

Conclusions:

• In vitro-reconstituted VLPs represent a promising platform for in vivo CAR T cell gene delivery.
• This approach may offer a more efficient and scalable alternative to traditional CAR T cell therapy.
• Further in vivo studies are warranted to confirm therapeutic potential.